236 related articles for article (PubMed ID: 24423642)
21. Experimental Autoimmune Myasthenia Gravis (EAMG): from immunochemical characterization to therapeutic approaches.
Fuchs S; Aricha R; Reuveni D; Souroujon MC
J Autoimmun; 2014 Nov; 54():51-9. PubMed ID: 24970384
[TBL] [Abstract][Full Text] [Related]
22. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4.
Im SH; Barchan D; Maiti PK; Fuchs S; Souroujon MC
J Immunol; 2001 Jun; 166(11):6893-8. PubMed ID: 11359850
[TBL] [Abstract][Full Text] [Related]
23. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis.
Yang H; Kala M; Scott BG; Goluszko E; Chapman HA; Christadoss P
J Immunol; 2005 Feb; 174(3):1729-37. PubMed ID: 15661938
[TBL] [Abstract][Full Text] [Related]
24. Delivery of an miR155 inhibitor by anti-CD20 single-chain antibody into B cells reduces the acetylcholine receptor-specific autoantibodies and ameliorates experimental autoimmune myasthenia gravis.
Wang YZ; Tian FF; Yan M; Zhang JM; Liu Q; Lu JY; Zhou WB; Yang H; Li J
Clin Exp Immunol; 2014 May; 176(2):207-21. PubMed ID: 24387321
[TBL] [Abstract][Full Text] [Related]
25. T-bet deficiency decreases susceptibility to experimental myasthenia gravis.
Liu R; Hao J; Dayao CS; Shi FD; Campagnolo DI
Exp Neurol; 2009 Dec; 220(2):366-73. PubMed ID: 19818352
[TBL] [Abstract][Full Text] [Related]
26. Suppression of experimental myasthenia gravis, a B cell-mediated autoimmune disease, by blockade of IL-18.
Im SH; Barchan D; Maiti PK; Raveh L; Souroujon MC; Fuchs S
FASEB J; 2001 Oct; 15(12):2140-8. PubMed ID: 11641240
[TBL] [Abstract][Full Text] [Related]
27. A dual altered peptide ligand down-regulates myasthenogenic T cell responses and reverses experimental autoimmune myasthenia gravis via up-regulation of Fas-FasL-mediated apoptosis.
Aruna BV; Ben-David H; Sela M; Mozes E
Immunology; 2006 Jul; 118(3):413-24. PubMed ID: 16827902
[TBL] [Abstract][Full Text] [Related]
28. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
Xiao BG; Duan RS; Zhu WH; Lu CZ
Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
[TBL] [Abstract][Full Text] [Related]
29. MuSK induced experimental autoimmune myasthenia gravis does not require IgG1 antibody to MuSK.
Küçükerden M; Huda R; Tüzün E; Yılmaz A; Skriapa L; Trakas N; Strait RT; Finkelman FD; Kabadayı S; Zisimopoulou P; Tzartos S; Christadoss P
J Neuroimmunol; 2016 Jun; 295-296():84-92. PubMed ID: 27235354
[TBL] [Abstract][Full Text] [Related]
30. Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice.
Maruta T; Oshima M; Mosier DR; Atassi MZ
Autoimmunity; 2017 Aug; 50(5):293-305. PubMed ID: 28548588
[TBL] [Abstract][Full Text] [Related]
31. Experimental autoimmune myasthenia gravis in B10.BV8S2 transgenic mice: preferential usage of TCRAV1 gene by lymphocytes responding to acetylcholine receptor.
Kaul R; Wu B; Goluszko E; Deng C; Dedhia V; Nabozny GH; David CS; Rimm IJ; Shenoy M; Haqqi TM; Christadoss P
J Immunol; 1997 Jun; 158(12):6006-12. PubMed ID: 9190955
[TBL] [Abstract][Full Text] [Related]
32. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis.
Sheng JR; Li LC; Ganesh BB; Prabhakar BS; Meriggioli MN
Clin Immunol; 2008 Aug; 128(2):172-80. PubMed ID: 18502693
[TBL] [Abstract][Full Text] [Related]
33. Complement regulator CD59 deficiency fails to augment susceptibility to actively induced experimental autoimmune myasthenia gravis.
Tüzün E; Saini SS; Morgan BP; Christadoss P
J Neuroimmunol; 2006 Dec; 181(1-2):29-33. PubMed ID: 17056125
[TBL] [Abstract][Full Text] [Related]
34. Atorvastatin-modified dendritic cells in vitro ameliorate experimental autoimmune myasthenia gravis by up-regulated Treg cells and shifted Th1/Th17 to Th2 cytokines.
Li XL; Liu Y; Cao LL; Li H; Yue LT; Wang S; Zhang M; Li XH; Dou YC; Duan RS
Mol Cell Neurosci; 2013 Sep; 56():85-95. PubMed ID: 23541702
[TBL] [Abstract][Full Text] [Related]
35. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
Atassi MZ; Oshima M; Deitiker P
Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
[TBL] [Abstract][Full Text] [Related]
36. Acetylcholine receptor-induced experimental myasthenia gravis: what have we learned from animal models after three decades?
Baggi F; Antozzi C; Toscani C; Cordiglieri C
Arch Immunol Ther Exp (Warsz); 2012 Feb; 60(1):19-30. PubMed ID: 22159475
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory IgG receptor FcgammaRIIB fails to inhibit experimental autoimmune myasthenia gravis pathogenesis.
Li J; Tüzün E; Wu XR; Qi HB; Allman W; Saini SS; Christadoss P
J Neuroimmunol; 2008 Feb; 194(1-2):44-53. PubMed ID: 18207575
[TBL] [Abstract][Full Text] [Related]
38. The thymus in myasthenia gravis. Changes typical for the human disease are absent in experimental autoimmune myasthenia gravis of the Lewis rat.
Meinl E; Klinkert WE; Wekerle H
Am J Pathol; 1991 Nov; 139(5):995-1008. PubMed ID: 1951638
[TBL] [Abstract][Full Text] [Related]
39. Amelioration of experimental autoimmune myasthenia gravis rats by blood purification treatment using 4-mercaptoethylpyridine-based adsorbent.
Ren J; Bai Y; Hao L; Dong Y; Pi Z; Jia L
J Biomed Mater Res A; 2011 Sep; 98(4):589-95. PubMed ID: 21721115
[TBL] [Abstract][Full Text] [Related]
40. Metformin attenuates autoimmune disease of the neuromotor system in animal models of myasthenia gravis.
Cui Y; Chang L; Wang C; Han X; Mu L; Hao Y; Liu C; Zhao J; Zhang T; Zhang H; Zhang Y; Liu Y; Zhao W; Wang J; Liu X; Sun B; Wang G; Kong Q; Han J; Li H
Int Immunopharmacol; 2019 Oct; 75():105822. PubMed ID: 31437793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
